Welcome to the Working Group on New TB Drugs
The mission of the Working Group on New TB Drugs is to ensure stakeholders in TB Drug Development from academia, government, industry, non-profit organizations, and patients themselves, are working together to facilitate and speed the development of new drugs for the treatment of tuberculosis.
One of the Stop TB Partnership's seven Working Groups, the Working Group on New Drugs (WGND) is a network of experts committed to accelerating the development of effective and affordable new therapies for TB.
Today's TB drug regimen takes too long to be effective and requires too many medications. Treatment of drug-sensitive disease requires 6-9 months whereas treatment of drug-resistant TB is even lengthier, taking 18-24 months or longer.
With the aim of increasing efficiency and coordination of the global TB drug R&D enterprise through information exchange, the WGND conducts an annual survey of the global TB drugs pipeline.
Working Group Documents
> 2009 WGND Terms of Reference
> WGND Strategic Plan
Stop TB Documents
> Stop TB Global Plan
> Google World TB Day Press
The WGND is composed of diverse interested stakeholders in TB drug development, including those working in TB drug R&D, regulators, public health workers, funders, community representatives, advocates and policy-makers.
Total members: 119
WGND Members:
Tibotec
